Findings Support Venetoclax Plus HMAs for Patients With AML Ineligible for Intensive Chemo

Data presented at the recent 2018 American Society of Hematology Annual Meeting demonstrated similar complete response rates between venetoclax plus azacitidine or decitabine in older patients with acute myeloid leukemia who were unable or unfit to receive standard intensive chemotherapy due to its toxicities, further supporting the FDA’s recent accelerated approval of venetoclax plus azacitidine, decitabine, or low-dose cytarabine in newly diagnosed older patients or those ineligible for intensive chemotherapy.

Targeted Oncology